IMR Press / FBL / Volume 11 / Issue 1 / DOI: 10.2741/1872

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
DNA vaccines for cancer
Show Less
1 Department of Medicine, Division of Hematology and Oncology, and the Comprehensive Cancer Center, University of Alabama at Birmingham
Academic Editor:Howard Kaufman
Front. Biosci. (Landmark Ed) 2006, 11(1), 1189–1198; https://doi.org/10.2741/1872
Published: 1 January 2006
(This article belongs to the Special Issue Cancer vaccine)
Abstract

DNA vaccines, also referred to as genetic, plasmid or polynucleotide vaccines, represent a relatively simple and economical method to exploit gene transfer for immunization against tumor associated antigens. This review discusses the potential advantages of DNA vaccines for cancer immunotherapy as compared to conventional protein vaccines and viral vectors. The proposed mechanisms responsible for induction of immune responses following DNA-based immunization are summarized. The preclinical development of DNA vaccines and the clinical experience with DNA immunization for cancer to date are reviewed. The low toxicity associated with DNA vaccines favors its further development, but additional strategies to improve the potency of this approach are needed if it is to be successfully integrated into the clinical setting.

Share
Back to top